Survival and glycemic control in patients with colorectal cancer and diabetes mellitus

Nina J Karlin; Shailja B Amin; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Curtiss B Cook

doi:10.4155/fsoa-2018-0044

Survival and glycemic control in patients with colorectal cancer and diabetes mellitus

Future Sci OA. 2018 Aug 15;4(9):FSO335. doi: 10.4155/fsoa-2018-0044. eCollection 2018 Oct.

Authors

Nina J Karlin^{1

1}, Shailja B Amin^{1

1}, Heidi E Kosiorek^{2

2}, Matthew R Buras^{2

2}, Patricia M Verona^{3

3}, Curtiss B Cook^{4

5

4

5}

Affiliations

¹ Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
² Biostatistics, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
³ Department of Information Technology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
⁴ Division of Endocrinology, Mayo Clinic, Scottsdale, AZ 85259, USA.
⁵ Division of Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.

Abstract

Aim: The impact of diabetes mellitus (DM) on survival in patients with colorectal cancer and the impact of colorectal cancer on glycemic control were examined.

Materials & methods: Patients with colorectal cancer with and without DM were matched 1:1 (2007-2015). Characteristics were compared between the two groups and survival assessed with the Kaplan-Meier method. Mixed models compared hemoglobin A_1c and glucose levels over time.

Results: In both groups, glucose values decreased during the year following cancer diagnosis (p < 0.001). 5-year overall survival was 56% (95% CI: 42-68%) for DM patients versus 57% (95% CI: 43-69%) for non-DM patients (p = 0.62).

Conclusion: DM did not adversely impact survival of patients with colorectal cancer. Colorectal cancer did not affect glycemic control.

Keywords: cancer; colorectal cancer; diabetes; endocrinology; glycemic control; outcomes research.